TQB3702
TQB3702 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for non-Hodgkin lymphoma.
Overview
TQB3702 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in non-Hodgkin lymphoma. Described in the registry record as a tyrosine kinase inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a tyrosine kinase inhibitor; the trial entries below carry the sponsor's wording.
1.TQB3702 slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"TQB3702" OR ABSTRACT:"TQB3702") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB3702, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentTQB2868
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tags pipeline, registry-only.
- TreatmentTQB3909
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tags pipeline, registry-only.
- TreatmentSTP938
Shares Non-Hodgkin lymphoma (all types) and the tags pipeline, registry-only.
- TreatmentAdavosertib
Shares the tags pipeline, registry-only.
- TreatmentAlisertib
Shares the tags pipeline, registry-only.
- TreatmentAMO959
Shares the tags pipeline, registry-only.
- TreatmentAMT-116
Shares the tags pipeline, registry-only.
- TreatmentARD103
Shares the tags pipeline, registry-only.